In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 351 to 400 of 434

TitleTypeExpected publication date
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Technology appraisal guidance
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]Technology appraisal guidance
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Technology appraisal guidanceTBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]Technology appraisal guidanceTBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Technology appraisal guidance
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidanceTBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Technology appraisal guidanceTBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shockInterventional procedures guidance
Surgical mesh for ventral herniasHealth technology evaluationTBC
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected cancer updateQuality standardTBC
Suspected Cancer: recognition and referral (update)NICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidance
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Technology appraisal guidance
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Technologies to support self-monitoring of vision change for people with macular disease (provisional title)Health technology evaluationTBC
Technologies to support the rapid diagnosis of endometriosis (provisional title)Health technology evaluationTBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379Technology appraisal guidanceTBC
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Technology appraisal guidanceTBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Highly specialised technologyTBC
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All